ProCE Banner Activity

ALPHA: Phase III Long-term Data for Ravulizumab or Eculizumab With Add-on Danicopan or Placebo in Patients With PNH and cs-EVH

Conference Coverage

Long-term analysis of the phase III ALPHA trial demonstrated that the significant clinical benefit with danicopan add-on treatment to eculizumab or ravulizumab is maintained for up to 48 weeks in patients with paroxysmal nocturnal hemoglobinuria and clinically significant extravascular hemolysis.

Released: December 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.